Microbix to Present at Bloom Burton Investor Conference

Virtual Healthcare Investor Conference on April 20 & 21

MISSISSAUGA, Ontario, April 19, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), a life sciences innovator and exporter, announces that its CEO, Cameron Groome, has been invited to present at the 2021 Bloom Burton & Co. Healthcare Investor Conference, being held virtually from Toronto, Ontario, Canada, on April 20 and 21, 2021.

Microbix’s CEO will speak to its latest corporate presentation at 2:30 PM ET, on Wednesday, April 21 as a part of Track 3 of the Conference. Microbix will also participate in a series of one-on-one meetings with institutional investors on both days of the Conference. Microbix’ latest corporate presentation will be made available at www.microbix.com, along with its other business information and financial disclosures.

About Microbix Biosystems
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Microbix antigens enable the antibody tests of over 100 international diagnostics companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., D.I.D. Diagnostic International Distribution SpA, Labquality Oy, The Medical Supply Company of Ireland Ltd, R-Biopharm AG, and Seegene Canada Inc. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably viral transport medium (DxTM) to stabilize patient samples for lab-based molecular diagnostic testing and Kinlytic urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix is traded on the TSX and OTCQB, and headquartered in Mississauga, Ontario, Canada.